Cargando…

Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study

BACKGROUND: Patients with end-stage kidney disease on haemodialysis suffer from frequent complications requiring hospitalisation. Atrial fibrillation is a burdensome comorbidity amongst patients on haemodialysis. We aimed to assess frequency, reasons, and duration of hospitalisations in haemodialysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steiner, Daniel, Schmaldienst, Sabine, Lorenz, Matthias, Klauser-Braun, Renate, Pabinger, Ingrid, Ay, Cihan, Säemann, Marcus, Königsbrügge, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709737/ https://www.ncbi.nlm.nih.gov/pubmed/36451221 http://dx.doi.org/10.1186/s12959-022-00434-7

Ejemplares similares

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
por: Königsbrügge, Oliver, et al.
Publicado: (2019)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
por: Nopp, Stephan, et al.
Publicado: (2023)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital
por: Nopp, Stephan, et al.
Publicado: (2020)

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Epidemiology, risk profile, management, and outcome in geriatric patients with atrial fibrillation in two long-term care hospitals
por: Wagner, Gernot, et al.
Publicado: (2022)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant
por: Posch, Florian, et al.
Publicado: (2017)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis
por: Hell, Lena, et al.
Publicado: (2018)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation
por: Galea, Roberto, et al.
Publicado: (2023)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis
por: Abuhasira, Ran, et al.
Publicado: (2018)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Plasma Clot Properties in Patients with Pancreatic Cancer
por: Thaler, Johannes, et al.
Publicado: (2023)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences
por: Goel, Narender, et al.
Publicado: (2020)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Anticoagulation in atrial fibrillation: the present and the future
por: Dweck, Marc R, et al.
Publicado: (2012)

Anticoagulation for atrial fibrillation in active cancer
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Differences in hospitalisation between peritoneal dialysis and haemodialysis patients
por: van Eck van der Sluijs, Anita, et al.
Publicado: (2022)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

Achieving target international normalization ratio in haemodialysis patients with atrial fibrillation: is it feasible?
por: Tsagalis, Georgios, et al.
Publicado: (2011)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
por: Santangeli, Pasquale, et al.
Publicado: (2011)

The new oral anticoagulants in atrial fibrillation: an update
por: Verheugt, F. W. A.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qo8rqgjidjq97tuqonk6oqhu2e